154 related articles for article (PubMed ID: 17476463)
1. Protective effects of Fe-Aox29, a novel antioxidant derived from a molecular combination of Idebenone and vitamin E, in immortalized fibroblasts and fibroblasts from patients with Friedreich Ataxia.
Jauslin ML; Vertuani S; Durini E; Buzzoni L; Ciliberti N; Verdecchia S; Palozza P; Meier T; Manfredini S
Mol Cell Biochem; 2007 Aug; 302(1-2):79-85. PubMed ID: 17476463
[TBL] [Abstract][Full Text] [Related]
2. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants.
Jauslin ML; Meier T; Smith RA; Murphy MP
FASEB J; 2003 Oct; 17(13):1972-4. PubMed ID: 12923074
[TBL] [Abstract][Full Text] [Related]
3. A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy.
Jauslin ML; Wirth T; Meier T; Schoumacher F
Hum Mol Genet; 2002 Nov; 11(24):3055-63. PubMed ID: 12417527
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the relative antioxidant potency of L-ergothioneine and idebenone.
Dong KK; Damaghi N; Kibitel J; Canning MT; Smiles KA; Yarosh DB
J Cosmet Dermatol; 2007 Sep; 6(3):183-8. PubMed ID: 17760697
[TBL] [Abstract][Full Text] [Related]
5. Improved antioxidant effect of idebenone-loaded polyethyl-2-cyanoacrylate nanocapsules tested on human fibroblasts.
Palumbo M; Russo A; Cardile V; Renis M; Paolino D; Puglisi G; Fresta M
Pharm Res; 2002 Jan; 19(1):71-8. PubMed ID: 11837703
[TBL] [Abstract][Full Text] [Related]
6. Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia.
Rustin P; Rötig A; Munnich A; Sidi D
Free Radic Res; 2002 Apr; 36(4):467-9. PubMed ID: 12069112
[TBL] [Abstract][Full Text] [Related]
7. The protective effect of vitamin E, idebenone and reduced glutathione on free radical mediated injury in rat brain synaptosomes.
Cardoso SM; Pereira C; Oliveira CR
Biochem Biophys Res Commun; 1998 May; 246(3):703-10. PubMed ID: 9618276
[TBL] [Abstract][Full Text] [Related]
8. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
Seznec H; Simon D; Monassier L; Criqui-Filipe P; Gansmuller A; Rustin P; Koenig M; Puccio H
Hum Mol Genet; 2004 May; 13(10):1017-24. PubMed ID: 15028670
[TBL] [Abstract][Full Text] [Related]
9. Influence of the antioxidants vitamin E and idebenone on retinal cell injury mediated by chemical ischemia, hypoglycemia, or oxidative stress.
Rego AC; Santos MS; Oliveira CR
Free Radic Biol Med; 1999 Jun; 26(11-12):1405-17. PubMed ID: 10401604
[TBL] [Abstract][Full Text] [Related]
10. Friedreich's ataxia: from disease mechanisms to therapeutic interventions.
Lodi R; Tonon C; Calabrese V; Schapira AH
Antioxid Redox Signal; 2006; 8(3-4):438-43. PubMed ID: 16677089
[TBL] [Abstract][Full Text] [Related]
11. [Successful idebenone therapy of hypertrophic cardiomyopathy in Friedreich ataxia].
Kádár K
Orv Hetil; 2003 Jun; 144(25):1241-4. PubMed ID: 12901180
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia.
Di Prospero NA; Sumner CJ; Penzak SR; Ravina B; Fischbeck KH; Taylor JP
Arch Neurol; 2007 Jun; 64(6):803-8. PubMed ID: 17562928
[TBL] [Abstract][Full Text] [Related]
13. Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA.
Lee YK; Lau YM; Ng KM; Lai WH; Ho SL; Tse HF; Siu CW; Ho PW
Int J Cardiol; 2016 Jan; 203():964-71. PubMed ID: 26625322
[TBL] [Abstract][Full Text] [Related]
14. Estrogen protection in Friedreich's ataxia skin fibroblasts.
Richardson TE; Yang SH; Wen Y; Simpkins JW
Endocrinology; 2011 Jul; 152(7):2742-9. PubMed ID: 21540287
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients.
Artuch R; Aracil A; Mas A; Monrós E; Vilaseca MA; Pineda M
Neuropediatrics; 2004 Apr; 35(2):95-8. PubMed ID: 15127307
[TBL] [Abstract][Full Text] [Related]
16. Idebenone in patients with Friedreich ataxia.
Schöls L; Vorgerd M; Schillings M; Skipka G; Zange J
Neurosci Lett; 2001 Jun; 306(3):169-72. PubMed ID: 11406322
[TBL] [Abstract][Full Text] [Related]
17. Idebenone: an emerging therapy for Friedreich ataxia.
Meier T; Buyse G
J Neurol; 2009 Mar; 256 Suppl 1():25-30. PubMed ID: 19283347
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes in Friedreich's ataxia after withdrawal from idebenone.
Cook A; Boesch S; Heck S; Brunt E; Klockgether T; Schöls L; Schulz A; Giunti P
Acta Neurol Scand; 2019 Jun; 139(6):533-539. PubMed ID: 30887496
[TBL] [Abstract][Full Text] [Related]
19. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial.
Rustin P; Bonnet D; Rötig A; Munnich A; Sidi D
Neurology; 2004 Feb; 62(3):524-5; author reply 525; discussion 525. PubMed ID: 14872056
[No Abstract] [Full Text] [Related]
20. Comparative hepatoprotective effects of tocotrienol analogs against drug-induced liver injury.
Tan CY; Saw TY; Fong CW; Ho HK
Redox Biol; 2015; 4():308-20. PubMed ID: 25637740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
